HLVX HilleVax
- 1.960
- -0.020-1.01%
- 1.960
- 0.0000.00%
HilleVax News
Cautious Hold Rating on HilleVax, Inc: Balancing Strong Cash Reserves With Strategic Uncertainty
Stifel Maintains HilleVax(HLVX.US) With Hold Rating, Maintains Target Price $3
H.C. Wainwright Maintains HilleVax(HLVX.US) With Hold Rating, Maintains Target Price $2
HilleVax, Inc: Analyst Maintains Hold Rating Amid Vaccine Trial Setback and Strategic Shift
Oral vaccines have broad prospects. O'Brien, Homer, gives Vaxart (vaxart.US) an 'outperform' rating against the large cap market.
HilleVax, Inc.: Prudent Cost Management Amidst Trial Setbacks – Hold Rating Justified
HilleVax Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on HilleVax, Maintains $2 Price Target
HilleVax, Inc: Hold Rating Amid Vaccine Efficacy Concerns and Financial Uncertainty
Leerink Partners Downgrades HilleVax to Market Perform, Lowers Price Target to $2
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)
Stifel Downgrades HilleVax to Hold From Buy, Adjusts Price Target to $3 From $34
Hold Rating on HilleVax Amid Uncertainties of Vaccine Efficacy and Clinical Trial Outcomes
HilleVax, Inc: Hold Rating Justified by Clinical Trial Setbacks and Strategic Uncertainties
Hold Rating on HilleVax as Clinical Setbacks Complicate Investment Outlook
Analysts Conflicted on These Healthcare Names: HilleVax, Inc (HLVX), UnitedHealth (UNH) and Morphic Holding (MORF)
HilleVax Analyst Ratings
HilleVax Analyst Ratings
HC Wainwright & Co. : HillEvax (HLVX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $28.00.
HilleVax Analyst Ratings
No Data